Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 01, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,750,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,234.045 pence per share.
- Treasury Holdings: Following the purchase, GSK holds 473,064,158 shares in Treasury.
- Treasury Percentage: Treasury shares represent 8.52% of total voting rights.
- Shares in Issue: 5,552,126,281 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares due to the repurchase of 1,750,000 shares on November 01, 2007. Consequently, the total number of shares held in Treasury increased to 473,064,158. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. The document confirms compliance with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,552,126,281) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (473,064,158) and its impact on total voting rights (8.52%).
- Note that this filing is a notification of a specific transaction and does not contain quarterly or annual financial results.